Ecnoglutide: Reference Overview and Reconstitution Notes

Ecnoglutide is an experimental peptide being studied in metabolic and weight regulation research. It is not FDA-approved in the United States.

Ecnoglutide

What it is

Ecnoglutide (also known as XW003) is a long-acting peptide made by Sciwind Biosciences. A peptide is a small, protein-like molecule built from amino acids (the basic building blocks of all proteins). Ecnoglutide is a GLP-1 receptor agonist, which means it activates a specific "docking station" on cells called the GLP-1 receptor. Think of the receptor as a lock and ecnoglutide as a key built to fit it.

Ecnoglutide is modeled after a natural hormone called GLP-1. GLP-1 is an incretin hormone, a chemical signal your gut releases after eating to help your body manage blood sugar. Ecnoglutide has a fat molecule attached to it, a process called lipidation (or fatty-acid conjugation). That fat attachment helps the molecule stay in the body longer. It is built from natural amino acids and is designed for once-weekly use.

Ecnoglutide also has a specific bias toward a cell messenger called cAMP (cyclic adenosine monophosphate). cAMP is a chemical signal inside the cell that carries the message from the receptor to the rest of the cell, a bit like a relay runner passing a baton.

Research context and categorization

Ecnoglutide falls into the metabolic and weight regulation research category, alongside other GLP-1 receptor agonists. Published studies have looked at it for glycemic control (keeping blood sugar at steady, healthy levels) in adults with type 2 diabetes, and for body-weight reduction in adults who are overweight or obese. Researchers have also discussed it in connection with non-alcoholic fatty liver disease and broader cardiometabolic health (the combined study of heart function and metabolism).

U.S. Regulatory Status

These uses are still investigational (experimental and not yet approved) in the United States. Ecnoglutide is not FDA-approved, and the research described here is ongoing rather than confirmed or finalized.

Reported trial findings, such as changes in HbA1c (a standard lab measure of average blood sugar over roughly three months) or percentage of body weight lost, come from controlled study settings. They should not be read as guaranteed outcomes for any general use. Anyone reviewing this compound should treat it as an experimental reference material, not a finished, approved product in the U.S. market.

Key point: Ecnoglutide is an experimental reference material and is not FDA-approved for clinical use in the United States.

Status

• Regulatory status: Research-only / not FDA-approved. Ecnoglutide is investigational in the United States. Ecnoglutide injection has reportedly received marketing approval from China's National Medical Products Administration (NMPA) for chronic weight management, but that is a foreign-market approval and does not apply to the U.S. or predict any FDA action.
• Sport status: Not specifically listed on the WADA Prohibited List. WADA (the World Anti-Doping Agency) sets international rules on banned substances in sport. GLP-1 receptor agonists as a class, including semaglutide, are not currently prohibited. They appear on WADA's Monitoring Program, which tracks how often a substance shows up in testing without imposing sanctions, while the class remains under ongoing review. Ecnoglutide itself is not named on the Prohibited List, though class status can change in future annual revisions.

Reconstitution notes (general)

Concentration equals the milligrams of compound in the vial divided by the millilitres of bacteriostatic water added. For example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL.

Adjust the water volume to reach whatever working concentration a protocol calls for, and use the calculator at peptide calculator to check the math before drawing anything up.

Dilution and handling notes (compound-specific)

The clinical product is a ready-made injection, but research-grade material is usually supplied as a lyophilized (freeze-dried) powder. Before lab use, you add bacteriostatic water to dissolve it back into a liquid. This step is called reconstitution.

Published reconstitution data specific to ecnoglutide is limited. General handling therefore follows the practices used for the broader class of lipidated GLP-1 analogues it belongs to.

Concentration and Dissolution

Working concentrations for GLP-1 analogue research vials commonly fall in the low single-digit mg/mL range, often around 2.5 to 5 mg/mL. That range keeps the total volume manageable when a full vial is reconstituted. These peptides typically dissolve within about one to five minutes when water is added slowly, producing a clear, colorless liquid.

Handling Lipidated Peptides

Ecnoglutide is a fatty-acid-conjugated peptide, meaning it carries an attached fat molecule. That fat attachment makes it behave differently from simpler peptides. It is more likely to aggregate (clump together), turn cloudy, or thicken like a gel at high concentrations or if the solution pH (its level of acidity or alkalinity) shifts. It can also foam easily if shaken.

To ensure proper reconstitution, follow these practical steps:

• Keep the concentration moderate rather than pushing the vial to a very high mg/mL.
• Add the bacteriostatic water gently down the wall of the vial rather than squirting it straight onto the powder.
• Swirl rather than shake to limit foaming and protect the peptide structure.
• If the material does not fully clear, a few extra minutes of gentle swirling at room temperature usually resolves it. Discard the solution if it stays cloudy, thick, or shows visible particles.
• Do not freeze the reconstituted solution. Repeated freeze-thaw cycles can break down the peptide.

Handling and storage

To keep the peptide stable, follow these storage guidelines:

• Refrigerate the reconstituted vial at 2 to 8 degrees Celsius and keep it away from direct light.
• Wipe the rubber stopper with an alcohol swab before each access.
• Write the mix date on the vial and observe the general, roughly 4-week refrigerated window.
• Discard the vial if the contents turn cloudy or discolored, or if particles appear.

Related reading

• Mazdutide
• Pemvidutide
• Retatrutide
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is ecnoglutide (XW003) and how does it work?

Ecnoglutide (XW003) is a long-acting, lipidated GLP-1 receptor agonist from Sciwind Biosciences, built from natural amino acids. Fatty-acid conjugation extends its half-life; it activates the GLP-1 receptor with a cAMP-biased signaling profile.

Is ecnoglutide FDA-approved in the United States?

No. Ecnoglutide is investigational and not FDA-approved in the U.S. It has received NMPA marketing approval in China for weight management, but that foreign-market status does not apply to or predict any FDA regulatory action.

Is ecnoglutide prohibited in sport under WADA rules?

Ecnoglutide is not specifically named on the WADA Prohibited List. GLP-1 receptor agonists as a class appear on WADA's Monitoring Program, tracked in testing but not currently sanctioned, while the class remains under ongoing review.

What the research community gets wrong about ecnoglutide

Ecnoglutide (XW003) shows up in a lot of bench notes, and a few ideas about it get repeated even though they do not hold up. Here are the ones worth correcting when you are handling the vial.

• It is not a plain peptide. Ecnoglutide is lipidated, meaning it carries an attached fat molecule. That fat makes it more likely to clump, foam, or gel than a simple unmodified peptide, so gentle swirling (not shaking) matters more here than with many other research powders.
• The cAMP bias is a receptor property, not a handling instruction. Studies describe ecnoglutide as cAMP-biased at the GLP-1 receptor. That describes how the molecule signals in cell assays. It does not mean the powder dissolves faster, stores longer, or needs a special concentration at the bench.
• It is not the same molecule as semaglutide. The two are both GLP-1 analogues, but they have different sequences and different molecular formulas (ecnoglutide is C194H304N48O61 per PubChem). Handling notes borrowed from one are a starting reference, not a guarantee, for the other.
• Foreign approval does not standardize the research powder. The finished clinical product is a ready-made injection reviewed by a regulator. Research-grade lyophilized ecnoglutide is a different item, and its fill, mass, and purity can vary by lot. Weigh and label each vial on its own rather than assuming a fixed amount.
• Higher concentration is not automatically better. Pushing a lipidated peptide to a very high mg/mL raises the chance it turns cloudy or thickens. A moderate working concentration keeps the solution clear and easier to inspect.

From our bench: If you have reconstituted a research vial of ecnoglutide, we want your firsthand notes. How long did the powder take to fully clear after you added bacteriostatic water down the vial wall and swirled, and at what working concentration (mg/mL) did you mix it? Did you see any foaming, cloudiness, or gel-like thickening, and did a few extra minutes of gentle swirling resolve it? Send us your actual observations, with real times and concentrations from your own vials, and we will add the measured ranges here.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Chen et al., Discovery of ecnoglutide - a novel, long-acting, cAMP-biased GLP-1 analog, Molecular Metabolism 2023 (PubMed)
5. Ecnoglutide, PubChem Compound CID 162625103 (C194H304N48O61)
6. EECOH-1 phase 3 trial of ecnoglutide in type 2 diabetes, Nature Communications 2026 (PMC12881390)